---
schema_version: "secwatch.filing_event.v1"
accession: "0001773751-26-000019"
form_type: "8-K"
ticker: "HIMS"
cik: "0001773751"
company_name: "Hims & Hers Health, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:12:58.445660+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Hims & Hers FY2025 revenue up 59% to $2.35B, adj. EBITDA $318M; guides FY2026 rev $2.7-2.9B

## Summary
- Revenue $2.35B (+59% YoY); net income $128M; adj. EBITDA $318M vs $177M prior year.
- Q4 revenue $618M (+28% YoY); net income $20.6M; adj. EBITDA $66.3M.
- Subscribers at 2.5M (+13% YoY); monthly revenue per avg subscriber $83 (+28% YoY).
- FY2026 guidance: revenue $2.7-2.9B, adj. EBITDA $300-375M; excludes potential Eucalyptus acquisition.
- Non-GLP-1 revenue majority; compounded semaglutide access assumed in guidance.

## SEC filing metadata
- accession: 0001773751-26-000019
- form_type: 8-K
- ticker: HIMS
- cik: 0001773751
- company_name: Hims & Hers Health, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/0001773751-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20260223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001773751-26-000019
- JSON: https://secwatch.observer/filing/0001773751-26-000019.json
- Plain text: https://secwatch.observer/filing/0001773751-26-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.